

a.) Remarks

In the outstanding Office Action, the Examiner has requested that Applicants elect a single invention from Group I and II as follows;

Group I, claims 1, 3, 4 and 7-26 drawn to a medicament and kit comprising a combination of recombinant antibody that specifically binds to human CCR4 and at least one pharmaceutically active agent, and

Group II, claims 5 and 6, drawn to a process comprising treating tumor by administering the medicament.

In response, Applicants hereby elect Group II, claims 5 and 6, drawn to a process of treating tumor.

Whichever of Groups I-II is elected, Applicants are required to select for search a specific extracellular region to which the anti-CCR4 antibody binds, e.g., positions (i) 1-39, (ii) 98-112, (iii) 176-206 or (iv) 271-284 of SEQ ID NO:1 and identify the specific antibody doing so. In response, Applicants select positions 13 to 25 of the amino acid sequence represented by SEQ ID NO:1 as a specific extracellular region to which the anti-CCR4 antibody binds.

For the antibody identified above, the Examiner requests that Applicants identify various information noted at (a) to (f) at page 3 of the Office Action. In response,

- the SEQ ID NOS of CDR1, CDR2 and CDR3 of the heavy chain variable region are SEQ ID NOS:5, 6 and 7, respectively.
- the SEQ ID NOS of CDR1, CDR2 and CDR3 of the light chain variable are SEQ ID NOS:8, 9 and 10, respectively.

The Examiner requires Applicants to select a medicament with or without a pharmaceutically active agent and, if a pharmaceutically active agent is selected, to identify the agent as well. In response, Applicants select a medicament with a pharmaceutically active agent, and hereby identify G-CSF as such pharmaceutically active agent.

Finally, the Examiner also requests that Applicants identify a specific antibody and hybridoma producing the same. Although such are not mentioned in the specification, the hybridoma is KM8761. If the Examiner wishes that the specification be amended to refer to that hybridoma, Applicants will be happy to do so.

Entry hereof is earnestly solicited.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,

/Lawrence S. Perry/

Lawrence S. Perry
Attorney for Applicants
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

HE\ac

FCHS_WS 1494827_1.DOC